Plasma acetyl-l-carnitine and l-carnitine in major depressive episodes: a case-control study before and after treatment

被引：7

作者：

Tayeb, Abd El Kader Ait ^{[1
,2
]}

Colle, Romain ^{[1
,2
]}

El-Asmar, Khalil ^{[1
,3
]}

Chappell, Kenneth ^{[1
]}

Acquaviva-Bourdain, Cecile ^{[4
]}

David, Denis J. ^{[5
]}

Trabado, Severine ^{[6
,7
]}

Chanson, Philippe ^{[6
,8
]}

Feve, Bruno ^{[9
]}

Becquemont, Laurent ^{[1
,10
]}

Verstuyft, Celine ^{[1
,7
]}

Corruble, Emmanuelle ^{[1
,2
]}

机构：

[1] Univ Paris Saclay, Fac Med, INSERM, MOODS Team,CESP, F-94275 Le Kremlin Bicetre, France

[2] Hop Bicetre, AP HP, Serv Hosp Univ Psychiat Bicetre, Hop Univ Paris Saclay, F-94275 Le Kremlin Bicetre, France

[3] Amer Univ Beirut, Fac Hlth Sci, Dept Epidemiol & Populat Hlth, Beirut, Lebanon

[4] Hosp Civils Lyon, Grp Hosp Est GHE, Ctr Biol & Pathol Est, Serv Malad Hereditaires Metab & Depistage Neonata, Bron, France

[5] Univ Paris Saclay, Fac Pharm, INSERM, CESP,MOODS Team, Chatenay Malabry, France

[6] Univ Paris Saclay, Fac Med, INSERM UMR S U1185, F-94275 Le Kremlin Bicetre, France

[7] Hop Bicetre, AP HP, Hop Univ Paris Saclay, Serv Genet Mol Pharmacogenet & Hormonol Bicetre, F-94275 Le Kremlin Bicetre, France

[8] Hop Bicetre, AP HP, Ctr Reference Malad Rares Hypophyse, Serv Endocrinol & Malad Reprod, F-94275 Le Kremlin Bicetre, France

[9] Sorbonne Univ, Hop St Antoine, AP HP,CRMR PRISIS,INSERM, Serv Endocrinol,Inst Hosp Univ ICAN,Ctr Rech St A, F-75012 Paris, France

[10] Hop Bicetre, AP HP, Hop Univ Paris Saclay, Ctr Rech Clin, F-94275 Le Kremlin Bicetre, France

来源：

PSYCHOLOGICAL MEDICINE | 2023年 / 53卷 / 06期

关键词：

Acetyl-l-carnitine; antidepressants; biomarkers; l-carnitine; major depressive disorder; major depressive episodes; mitochondria; L-ACETYLCARNITINE; DOUBLE-BLIND; ANTIDEPRESSANTS; ACYLCARNITINES; MITOCHONDRIA; MULTICENTER; DISORDER; PLACEBO; RATS;

D O I：

10.1017/S003329172100413X

中图分类号：

B849 [应用心理学];

学科分类号：

040203 ;

摘要：

Background Major depressive disorder (MDD) is the main cause of disability worldwide, its outcome is poor, and its underlying mechanisms deserve a better understanding. Recently, peripheral acetyl-l-carnitine (ALC) has been shown to be lower in patients with major depressive episodes (MDEs) than in controls. l-Carnitine is involved in mitochondrial function and ALC is its short-chain acetyl-ester. Our first aim was to compare the plasma levels of l-carnitine and ALC, and the l-carnitine/ALC ratio in patients with a current MDE and healthy controls (HCs). Our second aim was to assess their changes after antidepressant treatment. Methods l-Carnitine and ALC levels and the carnitine/ALC ratio were measured in 460 patients with an MDE in a context of MDD and in 893 HCs. Depressed patients were re-assessed after 3 and 6 months of antidepressant treatment for biology and clinical outcome. Results As compared to HC, depressed patients had lower ALC levels (p < 0.00001), higher l-carnitine levels (p < 0.00001) and higher l-carnitine/ALC ratios (p < 0.00001). ALC levels increased [coefficient: 0.18; 95% confidence interval (CI) 0.12-0.24; p < 0.00001], and l-carnitine levels (coefficient: -0.58; 95% CI -0.75 to -0.41; p < 0.00001) and l-carnitine/ALC ratios (coefficient: -0.41; 95% CI -0.47 to -0.34; p < 0.00001), decreased after treatment. These parameters were completely restored after 6 months of antidepressant. Moreover, the baseline l-carnitine/ALC ratio predicted remission after 3 months of treatment (odds ratio = 1.14; 95% CI 1.03-1.27; p = 0.015). Conclusions Our data suggest a decreased mitochondrial metabolism of l-carnitine into ALC during MDE. This decreased mitochondrial metabolism is restored after a 6-month antidepressant treatment. Moreover, the magnitude of mitochondrial dysfunction may predict remission after 3 months of antidepressant treatment. New strategies targeting mitochondria should be explored to improve treatments of MDD.

引用

页码：2307 / 2316

页数：10

共 47 条

[21] Impaired mitochondrial function in psychiatric disorders [J].